MedTrace Logo

Bioequivalence Study of Hydrochlorothiazide 50mg Tablets Under Fasting Conditions

NCT00776646 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2008-10-21

No results posted yet for this study

Summary

To compare the single-dose oral bioavailability of hydrochlorothiazide 50 mg tablet of Ohm Laboratories (A subsidiary of Ranbaxy pharmaceuticals USA) with hydrochlorothiazide 50 mg tablet of IVAX Pharmaceuticals, USA in healthy, adult, human, male subjects under fasting condition

Conditions

  • Healthy

Interventions

DRUG

hydrochlorothiazide 50 mg tablet

Sponsors & Collaborators

  • IPCA Laboratories Ltd.

    collaborator INDUSTRY

  • Ranbaxy Laboratories Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2006-06-30
Completion
2006-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00776646 on ClinicalTrials.gov